低体积寡复发激素敏感性前列腺癌适合病灶消融治疗的患病率与预后
这项前瞻性队列研究纳入208例原发治疗后生化复发且睾酮>50 ng/mL的前列腺癌患者,行18-F胆碱PET-CT评估复发灶。153例(74%)为低体积复发,55例(26%)为高体积复发;低体积复发3年去势抵抗前列腺癌无生存率88%,高体积复发为50%(P<0.001)。
要点
- 四分之三的PET-CT检出复发前列腺癌患者为低体积病变,可能适合局部治疗。
- 低体积复发患者3年CRPC无生存率88%,高体积复发为50%(P<0.001)。
- 淋巴结复发是最主要的失败模式,占检测部位的30%。
核心结论
- 四分之三的18-F胆碱PET-CT检出复发的前列腺癌患者为低体积病变,可能适合局部治疗。
- 低体积病变患者较高体积病变患者预后更好。
- 淋巴结复发是最主要的失败模式。
研究设计与样本
- 前瞻性队列研究,纳入符合18-F胆碱PET-CT检查条件、原发前列腺癌治疗后无症状生化复发且睾酮>50 ng/mL的患者208例。
- 按扫描计数病灶数,孤立局部复发或≤3处转移(伴或不伴局部复发)定义为低体积病变,>3处转移定义为高体积病变。
- 采用描述性统计报告复发情况,Cox回归分析预后变量对至发生去势抵抗前列腺癌(CRPC)时间的影响。
主要发现
- 208例患者共检出625处复发部位:淋巴结(N1/M1a)30%、骨18%、前列腺(床)11%、内脏4%、上述部位组合37%。
- 153例(74%)为低体积复发,55例(26%)为高体积复发。
- 全队列3年CRPC无生存率为79%(95%CI 43-55),低体积复发为88%,高体积复发为50%(P<0.001)。
- 复发时较长的PSA倍增时间和低体积病变与至CRPC时间较长相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To describe the anatomical patterns of prostate cancer (PCa) recurrence after primary therapy and to investigate if patients with low-volume disease have a better prognosis as compared with their counterparts. MATERIALS AND METHODS: Patients eligible for an 18-F choline positron-emission tomography (PET)-computed tomography (CT) were enrolled in a prospective cohort study. Eligible patients had asymptomatic biochemical recurrence after primary PCa treatment and testosterone levels >50 ng/mL. The number of lesions was counted per scan. Patients with isolated local recurrence (LR) or with ≤3 metastases (with or without LR) were considered to have low-volume disease and patients with >3 metastases to have high-volume disease. Descriptive statistics were used to report recurrences. Cox regression analysis was used to investigate the influence of prognostic variables on the time to developing castration-resistant PCa (CRPC). RESULTS: In 208 patients, 625 sites of recurrence were detected in the lymph nodes (N1/M1a: 30%), the bone (18%), the prostate (bed; 11%), viscera (4%), or a combination of any of the previous (37%). In total, 153 patients (74%) had low-volume recurrence and 55 patients (26%) had high-volume recurrence. The 3-year CRPC-free survival rate for the whole cohort was 79% (95% confidence interval 43-55), 88% for low-volume recurrences and 50% for high-volume recurrences (P < 0.001). Longer PSA doubling time at time of recurrence and low-volume disease were associated with a longer time to CRPC. CONCLUSIONS: Three out of four patients with PCa with a 18-F choline PET-CT-detected recurrence have low-volume disease, potentially amenable to local therapy. Patients with low-volume disease have a better prognosis as compared with their counterparts. Lymph node recurrence was the most dominant failure pattern.
引用
- De Bruycker A, Lambert B, Claeys T, et al. Prevalence and prognosis of low-volume, oligorecurrent, hormone-sensitive prostate cancer amenable to lesion ablative therapy. BJU Int. 2017. PMID: 28646594. doi:10.1111/bju.13938
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。